


The invention relates to the application of heteronuclear coordinative compounds in medicine, as well as to the use of dimera of the trihydrate aquaethylenediamine tetraacetatobismuthate(III) of 1,6-dinitro tetraminecobalt(III) and of the dihydrate ethylenediamine tetraacetatobismuthate(III) of oxalatotetraaminecobalt(III) as inhibitors of human leukemia. Summary of the invention consists in that in the capacity of inhibitors of human myeloid leukemia are claimed heteronuclear coordinative compounds of cobalt(III) and bismuth(III) of formula:



where X=NO₂ (I), 1/2 C₂O₄(II); Y=NH₃(I), 1/2 C₂O₄ (II); Z=NO₂ (I), NH₃ (II); n=3(I), 2 (II); O_w=H₂O (I), (II) is absent.

Claims: 1

Fig.: 1